Paramore C - Search Results

1

Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone.

Ben-Joseph R, Bell JA, Brixner D, Kansal A, Paramore C, Chitnis A, Holly P, S Burgoyne D. Ben-Joseph R, et al. Among authors: paramore c. J Manag Care Spec Pharm. 2016 Apr;22(4):358-66. doi: 10.18553/jmcp.2016.22.4.358. J Manag Care Spec Pharm. 2016. PMID: 27023689 Free PMC article.

2

Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone.

Ben-Joseph R, Bell JA, Chitnis A, Kansal A, Holly P, Paramore C, Wild H. Ben-Joseph R, et al. Among authors: paramore c. J Med Econ. 2016;19(2):169-80. doi: 10.3111/13696998.2015.1105810. Epub 2015 Dec 2. J Med Econ. 2016. PMID: 26451633 Free article.

3

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.

Kansal AR, Reifsnider OS, Brand SB, Hawkins N, Coughlan A, Li S, Cragin L, Paramore C, Dietz AC, Caro JJ. Kansal AR, et al. Among authors: paramore c. J Mark Access Health Policy. 2021 Jun 7;9(1):1922028. doi: 10.1080/20016689.2021.1922028. J Mark Access Health Policy. 2021. PMID: 34178295 Free PMC article.

4

Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.

Mauskopf JA, Paramore C, Lee WC, Snyder EH. Mauskopf JA, et al. Among authors: paramore c. J Manag Care Pharm. 2005 Apr;11(3):231-51. doi: 10.18553/jmcp.2005.11.3.231. J Manag Care Pharm. 2005. PMID: 15804207 Free PMC article.

5

Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review.

Oglesby A, Shaul AJ, Pokora T, Paramore C, Cragin L, Dennis G, Narayanan S, Weinstein A. Oglesby A, et al. Among authors: paramore c. Int J Rheumatol. 2013;2013:347520. doi: 10.1155/2013/347520. Epub 2013 Apr 3. Int J Rheumatol. 2013. PMID: 23762067 Free PMC article.

6

Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Coyne KS, et al. Among authors: paramore c. Value Health. 2006 Sep-Oct;9(5):348-56. doi: 10.1111/j.1524-4733.2006.00124.x. Value Health. 2006. PMID: 16961553 Free article.

7

Cost of illness of hyponatremia in the United States.

Boscoe A, Paramore C, Verbalis JG. Boscoe A, et al. Among authors: paramore c. Cost Eff Resour Alloc. 2006 May 31;4:10. doi: 10.1186/1478-7547-4-10. Cost Eff Resour Alloc. 2006. PMID: 16737547 Free PMC article.

8

Incorporating pharmacoeconomic and health outcomes into randomized clinical trials.

Revicki DA, Paramore C, Rentz AM. Revicki DA, et al. Among authors: paramore c. Expert Rev Pharmacoecon Outcomes Res. 2005 Dec;5(6):695-703. doi: 10.1586/14737167.5.6.695. Expert Rev Pharmacoecon Outcomes Res. 2005. PMID: 19807612

9

A review of the economic burden of ADHD.

Matza LS, Paramore C, Prasad M. Matza LS, et al. Among authors: paramore c. Cost Eff Resour Alloc. 2005 Jun 9;3:5. doi: 10.1186/1478-7547-3-5. Cost Eff Resour Alloc. 2005. PMID: 15946385 Free PMC article.

10

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.

Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Herring WL, et al. Among authors: paramore c. Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9. Online ahead of print. Pharmacoeconomics. 2024. PMID: 38684631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page